This trial is testing a new cholesterol-lowering injection to see if it safely lowers the risk of heart attacks and strokes.
1 Primary · 3 Secondary · Reporting Duration: Median follow-up of 5-years
Experimental Treatment
Non-Treatment Group
15000 Total Participants · 2 Treatment Groups
Primary Treatment: Inclisiran · Has Placebo Group · Phase 3
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: